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ABSTRACT
In myocardial infarction (MI), the occurrence of energy depletion, oxidative stress, and decreased amino acids 
metabolism alter tissue metabolites. Evidence has shown that tocotrienol-rich fraction (TRF) prevents myocardial injury 
in MI. However, the protective mechanism at the metabolite level is unknown. Male Sprague-Dawley rats were grouped 
into control, isoprenaline (ISO)-induced MI (MI), healthy rats receiving 200 mg/kg TRF (200TRF), and MI rats receiving 
200 mg/kg TRF (200TRF+MI) groups. TRF was administered via oral gavage daily for 12 weeks followed by 
intraperitoneal ISO injection (85 mg/kg) for two consecutive days at a 24-hour interval to induce MI. High-performance 
liquid chromatography was performed to analyze serum α-tocopherol and tocotrienol concentration whereas ultra-
high-performance liquid chromatography-mass spectrometry was used for the untargeted metabolomic study. Serum 
α-tocopherol but not tocotrienol was increased in the 200TRF (p=0.121) and 200TRF+MI (p<0.05) following TRF 
supplementation. Multivariate analysis by Orthogonal Projections to Latent Structures Discriminant Analysis showed 
high predictability of the group comparison models for MI vs control and 200TRF+MI vs MI (cross-validation: Q2>0.7, 
R2Y>0.8, p<0.05). A total of 84 and 37 metabolites [when covariance of p≥|0.05| (magnitude) and p(corr)≥|0.5| 
(reliability)] were significantly different in the myocardial homogenates of MI vs control and 200TRF+MI vs MI, 
respectively. MI rats had reduced S-adenosylmethionine and L-cystathionine that might worsen MI by disturbing 
glutathione metabolism; decreased phosphoribosyl-pyrophosphate and purine salvage process that might impair DNA 
synthesis, and elevated glucose-6-phosphate suggesting enhanced anaerobic glycolysis possibly for rapid production of 
energy. Conversely, TRF supplementation reversed the impaired metabolic pathways caused by MI.
Keywords: Isoprenaline; liquid chromatography-mass spectrometry; metabolomics; myocardial infarction; tocotrienol-
rich fraction
ABSTRAK
Dalam infarksi miokardium (MI), penurunan tenaga, tekanan oksidatif, serta pengurangan metabolisme asid amino 
mengubah metabolit dalam tisu. Bukti terkini menunjukkan bahawa fraksi kaya tokotrienol (TRF) mencegah kecederaan 
miokardium dalam MI. Namun, mekanisme perlindungannya pada tahap metabolit masih tidak diketahui. Tikus 
Sprague-Dawley jantan dibahagikan kepada kumpulan kawalan, MI aruhan isoprenalin (ISO) (MI), tikus sihat yang 
menerima 200 mg/kg TRF (200TRF), dan tikus MI yang menerima 200 mg/kg TRF (200TRF+MI). TRF diberikan melalui 
gavaj oral setiap hari selama 12 minggu diikuti suntikan ISO secara intraperitoneum (85 mg/kg) dua hari berturut-turut 
berselang 24 jam untuk mengaruh MI. Kromatografi cecair berprestasi tinggi digunakan untuk menganalisis kepekatan 
serum α-tokoferol dan tokotrienol manakala kromatografi cecair berprestasi ultra-tinggi-spektrometri jisim digunakan 
untuk kajian metabolomik tanpa sasaran. Serum α-tokoferol tetapi tidak tokotrienol telah meningkat bagi kumpulan 
200TRF (p=0.121) dan 200TRF+MI (p<0.05) setelah disuplementasi TRF. Analisis multivariat oleh Unjuran Ortogon 
kepada Analisis Diskriminasi Struktur Pendam menunjukkan kebolehramalan yang tinggi bagi model perbandingan 
antara kumpulan MI vs kawalan dan 200TRF+MI vs MI (pengesahan silang: Q2>0.7, R2Y>0.8, p<0.05). Sebanyak 84 
dan 37 metabolit [apabila kovarians p≥|0.05| (magnitud) dan p(corr)≥|0.5| (kebolehpercayaan)] berbeza secara 
signifikan dalam homogenat miokardium masing-masing bagi kumpulan MI vs kawalan dan 200TRF+MI vs MI. Tikus 
MI mengalami penurunan S-adenosilmetionina dan L-sistationina yang mungkin meningkatkan keterukan MI melalui 
gangguan metabolisme glutation; pengurangan fosforibosil-pirofosfat dan proses penyelamatan purina yang mungkin 
menjejaskan sintesis DNA, serta peningkatan glukosa-6-fosfat bagi proses glikolisis anaerob yang mungkin bertujuan 
menghasilkan tenaga secara pantas. Sebaliknya, suplementasi TRF menghalang penjejasan pada laluan metabolisma 
yang dicetuskan oleh MI.
Kata kunci: Fraksi kaya tokotrienol; infarksi miokardium; isoprenalin; kromatografi cecair-spektrometri jisim; 
metabolomik
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INTRODUCTION
Myocardial infarction (MI) is defined as clinical evidence 
of myocardial necrosis due to reduced oxygen supply to 
the heart (Thygesen et al. 2012). It is a part of a disease 
spectrum known as ischemic heart disease or coronary 
heart disease that causes 12.3% of total global deaths, 
translated to about 7.2 million deaths annually (Finegold 
et al. 2013; Sanchis-Gomar et al. 2016; World Health 
Organization 2017). Patients suffering from MI are 
becoming increasingly younger especially in some 
developing countries where it affects people aged 55-59 
years, in contrast to males aged 63-68 years and females 
aged 73-79 years in the developed countries (Institute of 
Medicine 2010; Seong & John 2016). Being one of the 
commonest causes of death combined with its high 
mortality and morbidity rate, the disease impacts not only 
the individuals who suffer from it, but also to the nation 
in terms of the overall productivity as well as financial 
burden in order to provide medical centers with adequate 
resources for the disease treatment (Che-Muzaini & 
Norsa’adah 2017; Lee et al. 2017).
High morbidity and mortality rates associated with 
MI has prompted extensive studies globally. To understand 
various aspects of the disease including identifying 
potential new treatment, several experimental animal 
models have been developed, including induction method 
via isoprenaline (ISO) administration through parenteral 
route (Murugesan et al. 2011; Panda et al. 2017). This is 
one of the most easily accessible, validated and commonly 
used technique to induce MI in rats. Also known as 
isoproterenol, ISO is a sympathomimetic agent that acts 
exclusively on β-adrenergic receptors with very little action 
on α-adrenergic receptors. Given the high β-adrenergic 
receptor expression in myocardial tissue (MIMS 2019), ISO 
administration produced significant effects on the heart. 
ISO causes positive chronotropism and inotropism which 
increase the rate as well as the force of cardiac contraction. 
However, it has no effect on α-receptors resulting in 
coronary arterial vasodilation that leads to hypotension in 
the coronary vascular bed. Cumulatively, ISO increases 
cardiac output and reduces diastolic as well as mean arterial 
pressure resulting in oxygen supply and demand mismatch 
leading to hypoxia (Biaggiono & Robertson 2014). 
Exposure to higher doses of ISO leads to ischemia with 
subsequent MI due to changes in various physiological 
processes in the myocardium including decreased global 
adenosine triphosphate (ATP) synthesis, increased oxidative 
damage, inflammation, and activation of apoptotic 
pathways along with cell necrosis (Liu et al. 2013; Siddiqui 
et al. 2016).
Untargeted metabolomics is the study of global 
metabolic profile in a biological system whereby all the 
low molecular weight compounds or metabolites that are 
present and participate in biochemical reactions at a certain 
time point will be captured and quantified (Horgan & 
Kenny 2011). Alterations of the metabolome are the end-
result of a series of changes that occur in the genomic, 
transcriptomic as well as proteomic levels. Metabolic 
profile can be influenced by diseases, lifestyle and dietary 
habit, along with other environmental factors such as 
exposure to pollutants and intake of medications (Clark-
Matott et al. 2015; Huang et al. 2014; Riera-Borrull et al. 
2017; Viana et al. 2016; Vlaanderen et al. 2017). Thus, 
studies that utilize metabolomic-based approach would 
provide insight regarding the overall molecular mechanisms 
of disease progression and how a therapeutic agent works 
at the metabolic level. Several authors have reported on 
the metabolic profile changes in MI by using biological 
samples from serum, plasma or myocardial tissue 
homogenate. By comparing MI rats with healthy controls, 
a number of altered biochemical pathways has been 
reported including β-oxidation of fatty acid, metabolism 
of amino acids such as glycine, serine, arginine and proline, 
and glycerophospholipid metabolism, among many others 
(Liu et al. 2013).
Recently, there have been increasing interests toward 
natural products in combating MI either to be used as 
preventive strategies or as an adjunct to the current 
pharmacological therapies. Cardioprotective effects of 
vitamin E have been discovered and studied for many years 
in both pre-clinical and clinical fields that show its 
promising future in the management of MI (Zarkasi et al. 
2019). Vitamin E is a general term used to describe 
naturally occurring compounds that share similar chemical 
structures and functions comprising several isomers of 
tocopherols and tocotrienols (Atia & Abdullah 2014). 
Many evidence suggests that tocotrienol is more powerful 
than tocopherol. For instance, the former provides a better 
anti-aging effect than the latter on senescent myoblasts 
(Khor et al. 2016). Furthermore, it possesses stronger anti-
inflammatory and antioxidant properties compared to 
tocopherol which may be contributed by its higher rate of 
cellular uptake as well as more uniform distribution in the 
plasma membrane (Fairus et al. 2006; Maniam et al. 2008; 
Ng & Ko 2012; Serbinova et al. 1991). Tocotrienol is 
present in foods of plant origin and it is most abundant in 
rice bran, palm oil and annatto seed (Kannappan et al. 
2012). Tocotrienol-rich fraction (TRF) can be obtained 
from serial processes of esterification, distillation, and 
concentration of its plant source (Top & Gapor 2005). It 
has been observed to reverse MI-related findings such as 
increased lactate dehydrogenase as well as aspartate and 
alanine aminotransferases in rat model attributing the 
effects toward its antioxidant property as well as its ability 
in stabilizing the proteasome (Bardhan et al. 2015; Das et 
al. 2008). Additionally, TRF at the dose of 200 mg/kg/day 
was reported to significantly decrease serum creatine 
kinase-myocardial band, which is a specific marker for 
myocardial injury, in ISO-induced MI rats (Zainalabidin et 
al. 2018). However, the cardioprotective mechanism of 
TRF on MI at the metabolic level is still unknown.
Therefore, the aim of this study was to determine the 
changes in metabolic profile caused by TRF on rats with 
ISO-induced MI.
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MATERIALS AND METHODS
TREATMENT OF ANIMALS AND COLLECTION OF 
SAMPLES
Male Sprague-Dawley rats (n=24) weighed 250-300 g were 
purchased from the Laboratory Animal Research Unit, 
Universiti Kebangsaan Malaysia (UKM) while ethical 
approval was obtained from the UKM Animal Ethics 
Committee (approval no. BIOK/PP/2018/ZAKIAH/23-
JAN./893-JAN.-2018-DEC.-2018-NAR-CAT2). They were 
kept in a well-ventilated room inside individual cages and 
were maintained at 25 ± 3℃, humidity of 40-60% with 12 
h light/dark cycle.
The rats were allowed to acclimatize for the first 
seven days prior to the commencement of the experiment 
following which they were randomly assigned into four 
groups (n=6 per group); control, MI, 200TRF, and 
200TRF+MI. Rats from all groups were given normal 
chow diet with access to tap water ad libitum . 
Supplementation of TRF (TRF Gold Tri.E 70, Sime 
Darby Research Sdn. Bhd., Klang, Selangor, Malaysia) 
at the dose of 200 mg/kg/day was administered to 
200TRF and 200TRF+MI groups via oral gavage for 12 
weeks. The TRF Gold Tri.E 70 contains 79.18% 
tocotrienol (that includes α-tocotrienol, β-tocotrienol, 
γ-tocotrienol, and δ-tocotrienol at 26.76%, 4.29%, 
32.60%, and 15.53%, respectively) as well as 20.81% 
α-tocopherol. The amount of different vitamin E isomers 
for each gram of TRF are 205.1 mg α-tocotrienol, 
32.9 mg β-tocotrienol, 249.8 mg γ-tocotrienol, 119 mg 
δ-tocotrienol, and 159.5 mg α-tocopherol. At the end of 
the study period, 85 mg/kg/day ISO was injected 
intraperitoneally to group MI and 200TRF+MI during 
the final two consecutive days with 24 h interval for MI 
induction (Madhesh & Vaiyapuri 2012; Madhesh et al. 
2011). The MI model has been validated in the previous 
study (Satirah et al 2018). ISO was replaced with normal 
saline for control and 200TRF groups. After two days, 
the rats were fasted overnight and anesthetized with 
intravenous KTX (ketamine, zoletil-50 and xylazine 
mixture) the following day. Blood samples were 
collected via retro-orbital sinus puncture and the rats 
were sacrificed via cervical dislocation.
Blood samples that were collected into plain tubes 
were allowed to clot for 15-30 min and centrifuged at 4,000 
rpm for 30 min while maintaining the temperature at 4℃. 
The supernatant (serum) was aliquoted to a new tube at 
0.5 mL each. The hearts were dissected, and left ventricles 
were harvested for metabolomic analysis. Sera and 
ventricular tissues were stored at -80℃ until further 
processing.
MEASUREMENT OF SERUM Α-TOCOPHEROL AND 
TOCOTRIENOL CONCENTRATION
Serum Sample Preparation
Sample preparation was performed according to Khan et 
al. (2010) with some modification. Briefly, serum samples 
were added with butylated hydroxytoluene (Sigma-
Aldrich, St. Louis, MI, USA) to reduce oxidation of the 
analyte of interest followed by addition of 100% ethanol 
(Merck, Darmstadt, Germany) for deproteinization. 
Liquid-liquid extraction was performed by vortexing the 
mixture followed by separation via centrifugation at 5,000 
rpm for 15 min while maintaining the temperature at 18℃. 
The supernatant was transferred to a new tube, mixed with 
n-hexane (Merck) and vortexed, resulting in a formation 
of three different layers from which the uppermost layer 
was collected and vacuum dried for 40 min. The dried 
sample was reconstituted with n-hexane and filtered 
through 0.2 µm regenerated cellulose membrane syringe 
filter (Minisart RC4, Sartorius Stedim Biotech, Göttingen, 
Germany) to remove impurities before it was injected into 
the high-performance liquid chromatography (HPLC) 
system for analysis.
HPLC System
All solvents used for determination of serum α-tocopherol 
and tocotrienol were HPLC-grade. Normal phase liquid 
chromatography was performed on a Shimadzu LC-10AT 
VP HPLC system controlled by Shimadzu Class-VP (version 
6.0) software (Shimadzu, Kyoto, Japan). Chromatographic 
separation was performed on Luna® Silica (2) column, 250 
mm length × 4.6 mm diameter, particle size 5 µm 
(Phenomenex, Torrance, CA, USA) with the column oven 
temperature maintained at 30℃ while the injection volume 
was 20 µL. The mobile phase consisted of a mixture 
between n-hexane and isopropanol (Merck) at 99:1 ratio 
with a flow rate of 1.5 mL/min under 38 kgf/cm2 of 
pressure. Analyte detection was performed by fluorescence 
detector when the excitation and emission wavelengths 
were set at 294 and 330 nm, respectively. Results obtained 
for each sample were compared to a standard curve for the 
determination of serum α-tocopherol and tocotrienol 
concentration (Jaafar et al. 2018).
METABOLOMIC ANALYSIS FROM                                       
HEART HOMOGENATE
Myocardial Tissue Sample Preparation
Myocardial tissue sample preparation was performed 
according to Marney et al. (2013) with some modifications. 
Briefly, the myocardial sample of the left ventricle was 
frozen with liquid nitrogen and crushed. For every 10 mg 
of heart tissue, 500 µL of chilled 80% methanol (Fischer 
Scientific, Hampton, NH, USA) was added followed by 
homogenization with a sonicator at 30 amp while on ice. 
Once homogenized, the sample was mixed with 300 µL 
chilled chloroform and centrifuged at 20,000 × g at 4℃ 
for 10 min. The supernatant was collected and vacuum 
dried. For every 10 mg of heart tissue used, 200 µL of 20% 
methanol was added to reconstitute the dried sample. The 
mixture was filtered to remove impurities before it was 
injected into the ultra-high-performance liquid 
chromatography-mass spectrometry (UHPLC-MS) system 
for analysis.
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UHPLC-Orbitrap MS System
All solvents for metabolomic analysis were MS-grade. 
Liquid chromatography was performed on UHPLC Dionex 
UltiMate™ 3000 Rapid Separation System coupled with Q 
Exactive™ HF hybrid quadrupole-Orbitrap mass 
spectrometer (Thermo Fischer Scientific) containing heated 
electrospray ionization probe (HESI-II). The system was 
controlled by Chromeleon Xpress and MS Thermo 
Xcalibur™ (version 4.0) system data. Chromatographic 
separation was performed by using reversed phase 
Syncronis™ C18 column, 100 mm length × 2.1 mm 
diameter, particle size 1.7 µm (Thermo Scientific) 
maintained at 55°C with an injection volume of 2 µL (n=3 
samples with 3 technical replicates for each sample).
Samples were randomly injected into the system while 
maintaining automatic sampler temperature at 10℃. The 
flow rate of the solvents was set at 0.45 mL/min using 
Optima® ultrapure water (Fischer Scientific) as mobile 
phase A and acetonitrile (Fischer Scientific) as mobile 
phase B where both contained 0.1% (v/v) formic acid 
(Thermo Fischer Scientific). Elution gradient program for 
15 min was set as followed: 0 min, 0.5% B; 5.5 min, 50% 
B; 6-12 min, 98% B; 13-15 min, 0.5% B. Positive and 
negative ionization modes were performed under these 
conditions: Sheath gas flow rate at 50 arbitrary unit (AU), 
auxiliary gas flow rate at 18 AU, sweep gas flow rate at 0 
AU, capillary temperature at 320℃ and spray voltage of 
3.5 kV for positive mode or 3.0 kV for negative mode. MS 
spectra were obtained using full MS/data-dependent MS2 
(TopN) (dd-MS2) by which MS2 was triggered when high-
intensity ion was discovered in full MS scan. Full MS scan 
parameters include: Default charge state of 1, resolution 
of 60,000, automatic gain control (AGC) of 1e6, maximum 
injection time (IT) of 120 ms, and a scan range between 
100-1,000 m/z.
Parameters for dd-MS2 scan were as followed: 
resolution of 15,000, AGC target of 5e4, maximum IT set 
at 50 ms, loop count of 5, TopN of 5, isolation window of 
1.5 m/z, and stepped normalized collision energy at 20, 40 
and 60. Settings for the dd include: Minimum AGC target 
of 8e2, intensity threshold at 1.6e4, exclude isotope ‘on’, 
and dynamic exclusion at 10 s. The MS system was 
calibrated by using Pierce LTQ ESI Positive Ion and Pierce 
LTQ ESI Negative Ion Calibration Solutions (Thermo 
Scientific). For quality control (QC), an aliquot of equal 
volume (2 µL) from each sample was pooled and mixed 
in a separate vial labeled as QC sample to assess the 
reproducibility and reliability of the LC-MS/MS system. 
The pooled QC sample was injected thrice prior to analysis 
of the individual sample and was repeated after every sixth 
sample injection.
Data Pre-processing
The data file ‘.RAW’ was processed with Thermo Scientific 
Compound Discoverer™ 2.0 (CD 2.0) software using 
untargeted workflow. This workflow used ‘Detect 
Unknown Compounds’ node to find chromatographic peaks 
for unknown compounds [molecular weight (m/w) × 
retention time (RT)] and ‘Predict Composition’ node to 
determine possible compositions of the elements that 
formed the compounds. Additionally, the workflow 
performed searches in mzCloud and ChemSpider databases 
to annotate unknown compounds that have been detected 
by the LC-MS system (Figure 1). This pre-processed data 
was then exported to the ‘.xlsx’ file for subsequent 
statistical analysis.
FIGURE 1. Workflow for data pre-processing in Thermo Scientific Compound Discoverer™ 2.0 (CD 2.0) whereby ‘Untargeted 
Metabolomic Analysis with Statistics’ approach was used followed by database search in mzCloud and ChemSpider to annotate the 
detected unknown compounds
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Multivariate Analysis
The peak areas for the detected metabolites were analyzed 
using the ‘Statistical Analysis’ module in MetaboAnalyst 
4.0 online software (Chong et al. 2018). The data was pre-
processed by subjecting to normalization processes that 
include quantile normalization to make the data distribution 
for different groups more identical, cube root transformation 
to adjust the data distribution toward normal distribution, 
and mean centering to eliminate offset data and focus on 
differences rather than similarities for each variable.
Unsupervised Principal Component Analysis (PCA) 
and supervised Orthogonal Projections to Latent Structures 
Discriminant Analysis (OPLS-DA) were used as multivariate 
analytical methods. In OPLS-DA, the covariance between 
X and Y had been maximized to identify which metabolites 
were responsible for separation between different rat 
groups. Furthermore, permutation test was done to assess 
the statistical significance of group separations with 
p-value set at ≤0.05. Differentially expressed metabolites 
(DEMs) were then selected if their covariance of p≥|0.05| 
(magnitude) and p(corr)≥|0.5| (reliability) on S plot of 
OPLS-DA (Jung et al. 2010; Suvagandha et al. 2014).
Metabolites Annotation
DEMs were annotated by cross-referencing the Human 
Metabolome Database (HMDB) (http://www.hmdb.ca/) and 
Metlin Library database (https://metlin.scripps.edu/) with 
mass accuracy set at 5 ppm (Durani et al. 2017). MS/MS 
spectra of putative metabolites were also compared with 
the online mzCloud database linked to CD 2.0 software or 
on its website (https://www.mzcloud.org/) before they were 
used for further analysis. Additionally, fold change analysis 
was also performed by comparing ‘MI vs control’ and 
‘200TRF+MI vs MI’ to determine the fold changes for these 
metabolites.
Pathway Analysis
Annotated DEMs were subsequently analyzed by using the 
‘Pathway Analysis’ module in the MetaboAnalyst 4.0 
software to obtain a clearer picture of the disturbed 
biochemical pathways in ISO-induced MI rats and the 
metabolic pathways changes following TRF supplementation 
in MI. For the mapping process, the metabolite library for 
Rattus norvegicus had been selected. The algorithm for 
pathway analysis was performed by applying the ‘Fischer 
exact test’ for over-representational analysis while 
‘relative-betweenness centrality; was selected for the 
analysis of the pathway topology. Metabolic pathways with 
impact-values > 0.1 were considered to be relevant (Durani 
et al. 2017).
STATISTICAL ANALYSIS
Data for serum α-tocopherol and tocotrienol was analyzed 
by using IBM Statistical Package for the Social Sciences 
(SPSS®) (version 23.0). Since the data distribution was 
skewed, central tendency and dispersion were expressed 
in median and interquartile range (IQR) while differences 
among groups were assessed by using non-parametric 
techniques.
RESULTS AND DISCUSSION
EFFECTS OF TRF ON SERUM Α-TOCOPHEROL AND 
TOCOTRIENOL CONCENTRATION
Measurement of serum α-tocopherol and tocotrienol 
concentrations was performed at the beginning and at the 
end of the study period. There was no difference for serum 
α-tocopherol among all rat groups at baseline. 
Supplementation with TRF was found to increase the serum 
α-tocopherol levels for 200TRF and 200TRF+MI rats at 
week 12 compared to the same group at baseline (Figure 
2(A)). Additionally, serum α-tocopherol for the 200TRF+MI 
group was significantly higher than MI rats with respective 
median (IQR) of 25.42 μg/mL (20.7-40.5 μg/mL) and 14.17 
μg/mL (12.6-17.6 μg/mL) (p<0.05). Supplementation of 
TRF produced a similar elevation of serum α-tocopherol 
in the 200TRF compared to control rats by 91.1% although 
the change was statistically insignificant (p=0.121). On the 
other hand, serum tocotrienol was similar at baseline for 
all rat groups. Supplementation with TRF for 12 weeks did 
not cause any change in the serum tocotrienol concentrations 
for 200TRF and 200TRF+MI compared to the same groups 
FIGURE 2. Changes in the serum α-tocopherol (A) and tocotrienol (B) concentrations (µg/mL) at baseline and week 12. Values 
are shown in median, error bars represent interquartile range (IQR). *Significantly differed from the same group at baseline with 
p<0.05. †Significantly differed from the MI group at week 12 with p<0.05. Abbreviations: MI (ISO-induced MI rats), 200TRF 
(healthy rats receiving 200 mg/kg/day TRF); 200TRF+MI (ISO-induced rats receiving 200 mg/kg/day TRF)
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at baseline. Similarly, serum tocotrienol levels did not differ 
between 200TRF and control as well as between 
200TRF+MI and MI groups at the end of the study period 
(Figure 2(B)).
These findings could be explained by the differences 
in biological processes involving transport and 
bioavailability of vitamin E within the blood circulation. 
Firstly, supplementation of vitamin E maximally increases 
the blood level of tocopherol and tocotrienol at a different 
time point. Administration of TRF orally in human subjects 
caused plasma α-tocotrienol to reach peak concentration 
earlier than α-tocopherol, recorded at about 4 h and 6 h, 
respectively. Additionally, post-prandial elevation of 
plasma α-tocotrienol was still significantly lower than 
α-tocopherol with a mean concentration of 4.79 ± 1.2 µg/
mL for the former and 13.46 ± 1.68 µg/mL for the latter 
(Fairus et al. 2006). Thus, findings on serum α-tocopherol 
and tocotrienol in this study might be affected by the 
differences in the bioavailability for both vitamin E 
vitamers.
Secondly, cellular uptake is higher for tocotrienol as 
compared to tocopherol. In a study using Jurkat cell line 
E6-1, α-tocotrienol reportedly entered the cell 70 times 
faster than α-tocopherol (Saito et al. 2004). As a result, 
tocotrienol might be subjected to higher clearance from 
blood circulation. Therefore, no differences were observed 
in the plasma tocotrienol concentration in rats receiving 
TRF supplementation compared to non-supplemented 
groups in the current study.
Thirdly, different protein carriers have different affinity 
for vitamin E vitamers and might affect its blood 
concentration. Majority of dietary vitamin E is transported 
by lipoproteins to reach peripheral tissues. However, the 
observed amount of tocopherols were higher than 
tocotrienols in chylomicron, low-density lipoprotein as 
well as high-density lipoprotein which stood at 
approximately 21%, 58% and 45%, respectively (Fairus 
et al. 2012). In addition, there is a special protein carrier 
for tocopherol transport in the blood circulation, especially 
for α and γ-isomers. It is an albumin protein family known 
as afamin (Dieplinger & Dieplinger 2015). Simulation 
study performed on the predicted tertiary structure of 
afamin found that the protein had 18 different binding sites 
for tocopherol alone (Voegele et al. 2002).
The explained mechanisms might lead to higher blood 
tocopherol level as compared to tocotrienol. Subsequently, 
any changes in relation to its concentration could be easily 
and clearly detected. Further study is needed to measure 
the level of vitamin E in the cardiac tissue for a better 
understanding of the relationship between bioavailability 
and efficacy of the cardioprotective effect of TRF.
METABOLIC PATHWAY CHANGES IN THE MYOCARDIAL 
TISSUE OF RATS WITH MI AND THE EFFECTS OF TRF 
SUPPLEMENTATION
Initial analysis by the PCA showed incomplete separation 
between MI and control groups, between 200TRF and 
control groups as well as between 200TRF+MI and MI 
groups. Therefore, multivariate analysis using OPLS-DA 
was performed to maximize the separation and to identify 
important metabolites that were responsible for the 
differences between those groups. OPLS-DA resulted in a 
clear separation between MI and control groups as well as 
between 200TRF+MI and MI groups but not between 
200TRF and control rats (Figure 3). Permutation tests for 
Q2 and R2Y were statistically significantly different for the 
comparisons between MI and control groups as well as 
between 200TRF+MI and MI groups, suggesting that these 
TABLE 1. Permutation test and cross-validation results for Orthogonal Projections to Latent Structures Discriminant Analysis 
(OPLS-DA)
Groups ESI Q2 p-Value Q2 R2Y p-Value R2Y
MI vs control
+ 0.752 <0.0005* 0.891 0.0265*
- 0.891 <0.0005* 0.998 <0.0005*
200TRF vs control
+ 0.230 0.0430* 0.385 0.3680
- 0.353 0.0160* 0.491 0.2055
200TRF+MI vs MI
+ 0.819 <0.0005* 0.951 0.0005*
0.731 0.0010* 0.993 0.0065*
*Statistically significant when p<0.05 in permutation test. Abbreviation: ESI (electrospray ionization). Cross-validation: Q2 = quality assessment, R2Y = degree of fit to 
the data
TABLE 2. The number of differentially expressed metabolites (DEMs) between different group comparisons
Groups
DEMs
Total Annotated Unannotated
ESI (+) ESI (-)
MI vs control 150 40 190 84 106
200TRF+ MI vs MI 69 16 85 37 48
ESI = electrospray ionization
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TABLE 3. List of annotated DEMs in between MI and control group
MI vs control
m/w Putative Metabolites Identifiers ESI FC
129.04280 5-Oxoproline HMDB0060262 + ↑ 14.26
163.12104 Acetylcysteine ^511 + ↑ 2.06
280.10608 Phenylalanyl-aspartate HMDB0028991 + ↑ 1.98
168.02847 Uric acid HMDB0000289 + ↑ 1.69
393.86701 2-(14,15-Epoxyeicosatrienoyl) glycerol ^4758 + ↓ 1.46
252.00116 2'-Deoxyinosine ^1187 + ↓ 1.45
459.35185 5-Methyltetrahydrofolic acid ^262 + ↓ 1.30
297.08974 5'-Methylthioadenosine HMDB0001173 + ↓ 1.24
340.27968 α-D-Glucose-1,6-bisphosphate ^1711 + ↓ 1.41
335.31899 β-Nicotinamide mononucleotide ^871 + ↓ 1.75
260.13719 γ-Glutamyl-L-isoleucine *62019 + ↓ 1.16
299.07701 D-4'-Phosphopantothenate HMDB0001016 + ↓ 1.53
429.90703 D-α-Tocopherol ^328 + ↓ 2.01
159.12609 DL-2-Aminooctanoic acid HMDB0000991 + ↓ 1.98
219.99107 L-5-Hydroxytryptophan ^254 + ↓ 1.38
204.11107 L-Acetylcarnitine ^879 + ↓ 1.07
186.11880 L-Alanyl-L-proline ^461 + ↓ 1.35
240.13492 L-Anserine ^1308 + ↓ 1.69
267.97498 L-Homocysteine ^476 + ↓ 1.42
149.05120 L-Methionine HMDB0000696 + ↓ 1.78
117.07926 L-Valine HMDB0000883 + ↓ 1.27
115.06368 L-Proline HMDB0000162 + ↓ 1.40
309.10605 N-Acetylneuraminic acid ^1249 + ↓ 1.46
217.13166 O-Propanoylcarnitine HMDB0062514 + ↓ 2.08
181.07400 o-Tyrosine HMDB0006050 + ↓ 1.50
206.04355 (R)-Lipoic acid HMDB0001451 + ↓ 1.05
399.37128 S-Adenosylmethionine ^896 + ↓ 1.20
425.35075 Acylcarnitine C18:1 HMDB0005065 + ↓ 1.26
135.06165 Adenine 296 + ↓ 1.54
267.09692 Adenosine 297 + ↓ 2.00
226.10675 Carnosine HMDB0000033 + ↓ 1.01
483.46558 Cer(d18:0/12:0) HMDB0011758 + ↓ 1.22
511.49656 Cer(d18:0/14:0) HMDB0011759 + ↓ 1.22
539.52779 Cer(d18:0/16:0) HMDB0011760 + ↓ 1.24
567.55941 Cer(d18:0/18:0) HMDB0011761 + ↓ 1.21
595.59105 Cer(d18:0/20:0) HMDB0011764 + ↓ 1.29
555.52319 Cer(t18:0/16:0) HMDB0010697 + ↓ 1.22
243.08565 Cytidine HMDB0000089 + ↓ 1.57
347.06327 Deoxyguanosine 5'-monophosphate HMDB0001044 + ↓ 1.60
307.56758 Deoxyuridine monophosphate (dUMP) ^1196 + ↓ 1.42
450.34634 Geranylgeranyl pyrophosphate ^1288 + ↓ 1.37
188.11630 Glycyl-L-leucine ^430 + ↓ 1.51
283.09183 Guanosine HMDB0000133 + ↓ 2.27
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247.14209 Hydroxybutyrylcarnitine HMDB0013127 + ↓ 4.23
507.57505 Inosine triphosphate ^1236 + ↓ 1.06
228.14756 Leucylproline ^468 + ↓ 2.26
453.28596 Lysophosphatidylethanolamine(16:0) HMDB0011473 + ↓ 1.40
479.30161 Lysophosphatidylethanolamine(18:1) HMDB0011476 + ↓ 2.24
529.31731 Lysophosphatidylethanolamine(22:4) HMDB0011493 + ↓ 3.81
525.28588 Lysophosphatidylethanolamine(22:6) HMDB0011496 + ↓ 1.35
121.91751 Nicotinamide (niacinamide) ^517 + ↓ 1.31
122.58708 Nicotinic acid ^519 + ↓ 1.26
132.02470 Oxaloacetic acid ^1353 + ↓ 1.90
793.56342 PE(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)) *60664 + ↓ 3.34
437.29129 PE(P-16:0e/0:0) HMDB0011152 + ↓ 1.21
193.09526 Phenylacetylglycine ^540 + ↓ 6.82
164.04758 Phenylpyruvic acid ^1389 + ↓ 1.47
390.35369 Phosphoribosyl-pyrophosphate ^264 + ↓ 1.08
225.94431 Porphobilinogen ^1330 + ↓ 2.71
143.09489 Proline betaine HMDB0004827 + ↓ 2.05
218.12684 Propionylcarnitine ^884 + ↓ 1.26
383.10805 Succinyladenosine HMDB0000912 + ↓ 1.04
241.91824 Thymidine ^1230 + ↓ 2.05
112.02762 Uracil HMDB0000300 + ↓ 1.37
281.04194 1-Methyladenosine ^105 - ↑ 1.24
216.03884 2-C-Methyl-D-erythritol 4-phosphate *64013 - ↑ 2.38
133.03601 L-Aspartic acid ^462 - ↑ 1.89
131.06803 Creatine ^357 - ↑ 1.44
260.02867 Glucose-6-phosphate HMDB0001401 - ↑ 3.90
169.04910 Norepinephrine ^318 - ↑ 2.04
246.04947 Phosphatidylglycerol *186 - ↑ 1.82
226.08094 Porphobilinogen ^1330 - ↑ 1.82
168.02694 Uric acid ^753 - ↑ 1.80
233.90871 5-Methoxytryptophan ^2613 - ↓ 1.56
283.09054 8-Hydroxy-deoxyguanosine HMDB0003333 - ↓ 1.82
249.96666 γ-Glutamylcysteine ^427 - ↓ 1.99
222.01841 L-Cystathionine ^1829 - ↓ 1.48
204.02472 L-Tryptophan ^1830 - ↓ 1.25
189.06253 N-Acetyl-L-glutamic acid ^1832 - ↓ 1.78
218.05446 N-Acetylserotonin ^313 - ↓ 1.50
347.06214 Adenosine monophosphate (AMP) HMDB0000045 - ↓ 1.54
317.95390 Coenzyme Q2 ^379 - ↓ 1.45
148.07208 Mevalonic acid ^1338 - ↓ 1.82
167.02385 Quinolinic acid ^1262 - ↓ 1.53
Putative metabolites were annotated by cross-referencing the online databases including Human Metabolome Database (HMDB), Metlin (*) and mzCloud (^). Symbol: 
(↑) increased; (↓) decreased. Abbreviation: ESI (electrospray ionization); FC (fold change); m/w (molecular weight). The list was sorted according to ionization mode, 
up- or downregulation, followed by alphabetical order
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projections were not over-fit by OPLS-DA; while the 
permutation test for R2Y between 200TRF and control 
groups was insignificant (Table 1). For the former two 
group comparisons, Q2 and R2Y values based on cross-
validation were high (>70%), indicating that the projections 
had good predictability (Eritja et al. 2017).
A total of 190 metabolites were differentially 
expressed between MI rats and control groups with 84 of 
them were annotated by cross-referencing to the online 
databases (Table 2). On the other hand, a total of 85 
metabolites were differentially expressed between 
200TRF+MI and MI groups with 37 of them were annotated. 
Since OPLS-DA did not produce a distinct separation 
between 200TRF and control groups, the number of DEMs, 
as well as metabolites annotation procedures, were not 
performed.
Table 3 shows the list of annotated DEMs in between 
MI and control groups. Out of 84 metabolites, 64 were 
detected in positive ion mode while another 20 metabolites 
were found in negative ion mode.
Table 4 lists the annotated DEMs in between 
200TRF+MI and MI groups. From 37 annotated metabolites, 
30 and 7 metabolites were detected in positive and negative 
modes, respectively.
Pathway analysis based on annotated DEMs showed 
that MI and TRF supplementation affected several 
metabolic pathways in the rats’ myocardium. Comparing 
between MI and control as well as 200TRF+MI and MI 
groups, pathways that are relevant to both group 
comparisons include cysteine and methionine metabolism, 
nicotinate and nicotinamide metabolism, pentose 
phosphate pathway, as well as starch and sucrose 
metabolism (Figure 4).
Since MI induced by ISO administration produced 
marked myocyte loss as well as increased fibrosis within 
the subendocardium of rat’s left ventricular free wall 
(Brooks & Conrad 2009), this part of the heart was selected 
for metabolomic assessment in the current study. 
Metabolomic analysis utilizing UHPLC-Orbitrap MS 
followed by multivariate analysis using the OPLS-DA 
technique could differentiate and identify metabolic 
changes in the myocardial tissue of control, MI and 
200TRF+MI rats. Interestingly, non-supplemented MI 
resulted in alterations of different sets of biochemical 
processes than TRF-supplemented MI rats. This indicates 
that TRF might protect against MI from biochemical aspects 
dissimilar than during the disease development itself. 
Nevertheless, four metabolic pathways were observed to 
be affected in both MI vs control and 200TRF+MI vs MI 
group comparisons.
Cysteine and Methionine Metabolism
Methionine is an essential amino acid for humans with a 
recommended daily intake of 15 mg/kg/day (Kurpad et al. 
2003). Metabolism of methionine would produce 
intermediates such as S-adenosylmethionine (SAM), 
S-adenosylhomocysteine (SAH), homocysteine and 
L-cystathionine (Poloni et al. 2015). The enzyme 
cystathionine-β-synthase (CBS) is responsible for the 
synthesis of L-cystathionine from homocysteine (Koutmos 
et al. 2010). Furthermore, trans-sulfuration process of 
L-cystathionine by cystathionine-γ-lyase will transform it 
into cysteine, an initial substrate in glutathione (GSH) 
synthesis (Kabil et al. 2011).
Deficiency of CBS causes hyperhomocysteinemia, 
which is an established risk factor for cardiovascular 
disease that includes pre-mature MI (Ukachukwu et al. 
2012). An earlier study reported that CBS could be 
allosterically activated by SAM which also stabilized the 
enzyme and improved cell viability under oxidative stress 
condition (Prudova et al. 2006). In the current study, since 
the reduction of L-cystathionine as well as SAM occurred 
in the myocardial tissue of MI rats by 1.48 and 1.20 times 
compared to control, respectively, it gave an impression 
that destabilization of CBS might have occurred in MI. 
Using metabolomics approach in rat MI model induced by 
coronary artery ligation, Prudova et al. (2006) reported 
that myocardial SAM concentration decreased gradually 
in a time-dependent manner and downregulated significantly 
at day 10 post-MI (Nam et al. 2017), which was consistent 
with our findings.
TRF might protect myocardial tissue against MI by 
reversing these changes. In the current study, MI rats 
receiving TRF supplementation for 12 weeks had a 
significant elevation of L-cystathionine as well as SAM by 
1.97 and 1.95 times compared to MI group, respectively. 
These changes reflected that TRF might be able to activate 
CBS by increasing the expression of SAM, its allosteric 
activator. Subsequently, this would enhance conversion of 
homocysteine to L-cystathionine as well as drive 
glutathione production via cysteine synthesis. Indeed, the 
relation between vitamin E and SAM had been demonstrated 
in earlier work. When mouse primary hepatocyte was 
exposed to ethanol, the resulting increased oxidative stress 
led to a marked decrease of SAM/SAH ratio by 53% while 
treatment with vitamin E significantly prevented this 
alteration (Gyamfi & Wan 2006).
Therefore, inhibition of cysteine and methionine 
metabolism in MI might have a direct impact on the 
antioxidative system via GSH synthesis due to decreased 
SAM production that was successfully reversed by TRF 
supplementation.
Nicotinate and Nicotinamide Metabolism
MI is strongly related to increased production of reactive 
oxygen species including hydrogen peroxide (H2O2) that 
leads to oxidative stress (Bae et al. 2016). The process of 
neutralizing H2O2 into water molecule requires concerted 
efforts by glutathione and co-factor nicotinamide adenine 
dinucleotide phosphate (NADP) (Arai et al. 2017; Berkholz 
et al. 2008). NADP is generated from nicotinate and 
nicotinamide metabolism. In this biochemical process, 
nicotinic acid and nicotinamide would be converted to 
nicotinamide adenine dinucleotide (NAD) via the Preiss-
Handler pathway and salvage pathway, respectively 
(Singhal & Cheng 2019). This would be followed by 
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TABLE 4. List of annotated DEMs in between ISO-induced MI rats receiving 200 mg/kg/day TRF and MI group
200TRF+MI vs MI
m/w Putative Metabolites Identifiers ESI FC
260.13719 γ-Glutamyl-L-isoleucine HMDB0011170 + ↑ 1.65
155.03487 L-Histidine ^473 + ↑ 1.59
399.37128 S-Adenosylmethionine ^896 + ↑ 1.95
267.09692 Adenosine HMDB0000050 + ↑ 1.53
511.49656 Cer(d18:0/14:0) HMDB0011759 + ↑ 1.97
539.52779 Cer(d18:0/16:0) HMDB0011760 + ↑ 2.96
543.33311 Lysophosphatidylcholine(20:4) HMDB0010395 + ↑ 7.90
437.29129 PE(P-16:0e/0:0) HMDB0011152 + ↑ 11.28
390.35369 Phosphoribosyl-pyrophosphate ^264 + ↑ 1.91
218.12684 Propionylcarnitine ^884 + ↑ 1.41
393.86701 2-(14,15-Epoxyeicosatrienoyl) glycerol ^4758 + ↓ 2.70
214.06244 2-Deoxyribose 5-phosphate ^1511 + ↓ 3.17
145.11044 3-Dehydroxycarnitine HMDB0006831 + ↓ 3.38
219.99107 L-5-Hydroxytryptophan ^1540 + ↓ 1.41
240.13492 L-Anserine ^1308 + ↓ 1.53
158.06931 L-Dihydroorotic acid ^1543 + ↓ 2.56
309.10605 N-Acetylneuraminic acid HMDB0000230 + ↓ 1.56
217.97662 N-Acetylserotonin ^313 + ↓ 1.48
206.04355 (R)-Lipoic acid HMDB0001451 + ↓ 1.30
260.02988 Glucose-6-phosphate HMDB0001401 + ↓ 2.85
111.08001 Histamine HMDB0000870 + ↓ 1.50
109.06441 Hypotaurine ^440 + ↓ 1.62
228.14756 Leucylproline HMDB0011175 + ↓ 2.74
121.91751 Nicotinamide (niacinamide) ^517 + ↓ 6.89
122.58708 Nicotinic acid ^519 + ↓ 3.07
506.26443 Phosphatidylglycerol *80008 + ↓ 4.44
143.09489 Proline betaine HMDB0004827 + ↓ 2.12
561.79007 Protoporphyrin IX ^1354 + ↓ 3.17
299.28268 Sphingosine HMDB0000252 + ↓ 1.90
427.36636 Stearoylcarnitine HMDB00848 + ↓ 2.05
249.96666 γ-Glutamylcysteine ^427 - ↑ 1.34
222.01841 L-Cystathionine ^1829 - ↑ 1.97
189.06253 N-Acetyl-L-glutamic acid ^1832 - ↑ 2.27
347.06214 Adenosine monophosphate (AMP) HMDB0000045 - ↑ 1.48
244.06850 Uridine HMDB0000296 - ↑ 1.61
131.06803 Creatine ^357 - ↓ 1.42
226.08094 Porphobilinogen ^1330 - ↓ 1.70
Putative metabolites were annotated by cross-referencing the online databases including Human Metabolome Database (HMDB), Metlin (*) and mzCloud (^). Symbol: 
(↑) increased; (↓) decreased. Abbreviation: ESI (electrospray ionization); FC (fold change); m/w (molecular weight). The list was sorted according to ionization mode, 
up- or downregulation, followed by alphabetical order
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FIGURE 3. Score plot for Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA). (A-B) ESI (+) and (-) for 
MI vs control; (C-D) ESI (+) and (-) for 200TRF vs control; (E-F) ESI (+) and (-) for 200TRF+MI vs MI. Each group consisted of 
three biological replicates with three technical replicates for every biological sample. Each point represents one replicate
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phosphorylation of NAD to NADP by NAD kinase (Love 
et al. 2015).
In the current study, reduction of nicotinic acid and 
nicotinamide (or niacinamide) occurred by 1.26 and 1.31 
times, respectively, in MI compared to control. Incidentally, 
γ-glutamylcysteine molecule, an intermediate in GSH 
synthesis (Wu et al. 2004), was also found to be decreased 
by 1.99 times indicating a disturbance in new GSH 
molecule production. From these findings, we could infer 
that myocardium might rely on pre-existing GSH in 
combating oxidative stress to form oxidized glutathione 
(GSSG), thus lowering the GSH itself. In fact, previous 
study reported that myocardial GSH concentration was 
reduced by approximately 40% during MI due to conversion 
from GSH to GSSG (Li et al. 2009). Reduced nicotinic acid 
and nicotinamide in heart homogenate of MI rats in the 
current study could be explained as a physiological 
response to limit oxidative damage where these molecules 
might be channeled into NAD and NADP syntheses to keep 
the pre-existing glutathione in its reduced state.
Supplementation of MI rats with 200 mg/kg/day TRF 
for 12 weeks resulted in further reduction of nicotinic acid 
and nicotinamide by 3.07 and 6.89 times compared to MI 
rats, respectively. However, they were accompanied by 
1.34 times increased of γ-glutamylcysteine expression 
which reflected that TRF might help in the generation of 
new GSH molecules. Report from the previous study could 
support this inference. By using rat model, MI group 
receiving vitamin E supplementation at the dose of 1,500 
U/kg/day for a short duration of 16 days had significantly 
increased myocardial GSH concentration from 37.4 ± 3.4 
nmol/g to 65.3 ± 5.0 nmol/g (p<0.05) as compared to non-
supplemented MI rats (Hill et al. 2005).
Pentose Phosphate Pathway
Myocardial tissue damage during MI is contributed by 
apoptosis and necrosis that lead to nuclear and mitochondrial 
deoxyribonucleic acid (DNA) release as well as increased 
purine metabolism (Casey et al. 2007; Fauconnier et al. 
2011). This process had been substantiated in the previous 
study whereby plasma DNA concentration derived from 
both nucleus and mitochondria elevated significantly in 
acute MI patients compared to control group (Wang et al. 
2015). As a result, serum metabolites involving purine 
degradation were also increased significantly (Al-Shamiri 
et al. 2009). Since there is a flux of damaged DNA and 
metabolites of purine degradation into the bloodstream 
from the infarcted heart, their concentrations naturally 
would decrease in the tissue itself. Certainly, metabolic 
profile in the current study found that myocardial adenosine 
and adenosine monophosphate (AMP) were decreased by 
2.00 and 1.54 times, respectively, in MI rats compared to 
control.
Pentose phosphate pathway is closely related to purine 
metabolism. The molecule phosphoribosyl-pyrophosphate 
(PRPP), which represented the pathway, is vital in purine 
salvage process (McCarthy et al. 2018). Availability of 
PRPP closely affected the rate of adenosine salvage in rat 
cardiomyocytes (Dow et al. 1987). Adenosine kinase could 
transform adenosine directly to AMP. Additionally, 
adenosine could be first converted to adenine before 
adenine phosphoribosyltransferase enzyme catalyzed an 
AMP-producing reaction that requires ribose phosphate 
moiety from PRPP (Buckoreelall et al. 2011; Frenguelli 
2019). Hence, in the current study, reduction of adenosine 
and AMP accompanied by reduced PRPP by 1.08 times 
indicated that there was a reduced purine salvage process 
due to impaired pentose phosphate pathway in MI.
Conversely, MI rats receiving TRF supplementation 
had a significant reversal of these changes than untreated 
MI group with an elevation of 1.53, 1.48 and 1.91 times 
each for adenosine, AMP and PRPP. These findings 
suggested that the cardioprotective mechanism of TRF 
might be related to the activation of the purine salvage 
FIGURE 4. Overview of pathway analysis showed altered metabolic pathways for (A) MI vs control and (B) 200TRF+MI vs MI. 
Affected pathways present in both group comparisons were marked with (*) and written in bold letters
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FIGURE 5. Overview of the altered metabolic profile and biochemical pathways in MI and the effects of TRF supplementation. 
Pathways involved are (1) Cysteine and methionine metabolism, (2) Nicotinate and nicotinamide metabolism, (3) Pentose 
phosphate pathway, and (4) Starch and sucrose metabolism. Symbol: Red arrow (metabolite changes in MI vs control), green 
arrow (metabolite changes in 200TRF+MI vs MI). Purine salvage pathway was marked with (*). Abbreviation: AMP (adenosine 
monophosphate), GSH (reduced glutathione), GSSG (oxidized glutathione), H2O (water), H2O2 (hydrogen peroxide), NADH 
(nicotinamide adenine dinucleotide), NADP+/NADPH (nicotinamide adenine dinucleotide phosphate), O2•- (superoxide), PRPP 
(phosphoribosyl-pyrophosphate), SAH (S-adenosylhomocysteine), SAM (S-adenosylmethionine)
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pathway in order to regenerate new substrates for DNA 
synthesis. Salvage pathway requires lower energy as 
compared to de novo purine synthesis (Moffatt & Ashihara 
2002). Cardiomyocytes had been reportedly suffered from 
reduced energy production in a hypoxic environment (Qiu 
et al. 2018). As such, this energy-saving process is very 
crucial in MI.
Starch and Sucrose Metabolism
During prolonged hypoxia, there is a sudden decrease in 
oxygen supply resulting in cardiac ischemia. The lack of 
oxygen causes mitochondria to function sub-optimally and 
disrupts the tricarboxylic acid (TCA) cycle, long-chain fatty 
acids β-oxidation and electron transfer through the electron 
transport chain resulting in rapid shortages of ATP 
generation (Mitra et al. 2015; Whitmer et al. 1978). This 
interference leads to conversion of aerobic to anaerobic 
glycolysis where the rate of glucose oxidation to lactate 
increases (Gandhi & Akholkar 2015).
Starch and sucrose metabolism represented by 
glucose-6-phosphate is another important metabolic 
pathway that was altered in both MI vs control and 
200TRF+MI vs MI group comparisons. The metabolite is 
a product of the initial reaction of anaerobic glycolysis 
catalyzed by glucokinase (Lenzen 2014). In the current 
study, glucose-6-phosphate was increased by 3.90 times 
in MI as compared to control rats which indirectly 
suggested that blood glucose concentration might be 
elevated as well. A cross-sectional study in human subjects 
found that the degree of MI severity was closely related to 
higher blood glucose readings at the time of hospital 
admission regardless of whether the patients had prior 
diabetes mellitus or not. MI patients with moderately high 
(7.8-11.0 mmol/L) and severely high (≥11.1 mmol/L) blood 
glucose had higher mortality risk than their euglycemic 
counterparts (Zhao et al. 2017). Furthermore, a study by 
Ali et al. (2016) utilizing gas chromatography-mass 
spectrometry and proton nuclear magnetic resonance 
techniques found that serum α- and β-glucose levels in 
acute MI patients were significantly raised, with p-value 
<0.0001 for each observation.
On the contrary, myocardial glucose-6-phosphate was 
significantly reduced by 2.85 times in 200TRF+MI 
compared to MI rats. From this finding, we could deduce 
that TRF supplementation might revert the anaerobic 
glycolysis back to aerobic process as well as improve 
overall glucose utilization within the myocardial tissue. 
Earlier study demonstrated that supplementation of α- and 
γ-tocopherol mixture significantly increased transcription 
of genes related to glycolysis (aldolase, enolase, and 
glucose phosphate isomerase), TCA cycle (isocitrate, 
succinate, and malate dehydrogenases) and ATP synthesis 
(mitochondrial F0, and F1 complexes of ATP synthase) in 
aged mouse brain (Park et al. 2008). Perhaps, a similar 
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mechanism might have occurred in the cardiac tissue of 
200TRF+MI rats whereby TRF might improve mitochondrial 
functions which directly enhanced aerobic glycolysis, TCA 
cycle as well as energy production in the form of ATP 
synthesis.
The roles of these metabolic pathways on the 
pathogenesis of MI and cardioprotective mechanisms of 
TRF worth further confirmatory studies to provide new 
insights for prevention and treatment of MI. Figure 5 
summarizes the metabolic profile and biochemical pathway 
changes that were involved in MI and the effects of TRF 
supplementation.
CONCLUSION
Supplementation of TRF increased serum α-tocopherol 
but not serum tocotrienol possibly due to the differences 
in the bioavailability of vitamin E’s vitamers. In ISO-
induced MI rats, TRF reversed the changes of metabolic 
pathways involving cysteine and methionine metabolism, 
nicotinate and nicotinamide metabolism, pentose 
phosphate pathway as well as starch and sucrose 
metabolism that were altered by MI. Ultimately, the 
changes brought by TRF might positively affect 
myocardial antioxidative system via new GSH production, 
activate adenosine salvage pathway possibly for DNA 
synthesis, and enhance glucose utilization through aerobic 
glycolysis.
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